Print
Email
Print Edition StoriesTuesday, July 8, 2008
Cambridge investors pump $13M into Accuri Cytometers
By Mass High Tech Staff
Two Cambridge private equity firms, Flagship Ventures and Fidelity Biosciences, have led a $13 million third-round financing of life sciences company Accuri Cytometers Inc. in Michigan. The funding will help expand commercialization of the Accuri C6 Flow Cytometer System, a cell analysis tool used in biomedical research, according to company reports.
Baird Venture Partners and Arboretum Ventures also invested in the funding.
As part of the deal, Bahaa Fam, venture partner with Fidelity Biosciences, and Harry Wilcox, partner with Flagship Ventures, will join Accuri’s board of directors.
Flagship Ventures, founded in 2000, claims a portfolio of more than 40 companies and $600 million in early-stage funding to manage. Its investment participation ranges through three sectors: therapeutics, life science tools and diagnostics, and bio-energy/clean tech.
Fidelity Biosciences is a division of Devonshire Investors, the private equity investment arm of Fidelity Investments.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
